To address these challenges, the CCTCC Core mCTA Working Group reviewed the mCTA text with the help of Innovative Medicines Canada and its member companies, HealthCareCAN and numerous provincial clinical trial bodies. Since many innovative pharmaceutical companies (including members of Innovative Medicines Canada) are participating in an international transcelerate initiative (CLEAR – Common Language Evaluation and Reconciliation) to address five controversial clauses in clinical trial contracts, the CLEAR clauses have also been made available for verification. Click here to learn more about these latest developments. The New Standard Agreement from the Department of Health raises questions about the NHS`s relationship with industry This agreement is not entirely new, but a revision of a 20034 document and a concept that has been studied in many legal systems5. which are carried out in NHS hospitals and are generally geared towards licensing pharmaceuticals. « It does not apply to Phase I tests performed on healthy volunteers (as in TGN1412), clinician-initiated studies, studies for which the sponsor only provides funding, or research at non-NHS institutions. . . .